

SCIENTIFIC PROGRAM

THURSDAY, SEPTEMBER 18, 2008 (CONT.)

18.00-19.30	ECTRIMS Council meeting (by invitation only)	Room 516A
19.15-20.15	Sponsored Satellite Symposium – Biogen Idec and Elan	Room 517D
	<p>Taking on MS – Targeting Defined Pathways Chair: Paul O'Connor (Toronto, Ontario, Canada)</p> <p>Taking the 1st step in addressing the entire disability picture Heinz Weindl (Wurzburg, Germany)</p> <p>Taking a step closer towards freedom from disease activity Howard Rossman (Farmington Hills, Michigan, USA)</p>	

EVALUATE THE WORLD CONGRESS SCIENTIFIC PROGRAM AND
CLAIM YOUR CME CERTIFICATE ONLINE WWW.MSMONTREAL.ORG

FRIDAY, SEPTEMBER 19, 2008

7.45-8.45	Sponsored Satellite Symposium – Novartis	Room 517
	<p>Oral Fingolimod: From Innovative Science to Clinical Promise Co-Chairs: Chris Polman (Amsterdam, Netherlands) and Jack Antel (Montréal, Québec, Canada)</p>	
07.45	Welcome and Introduction Chris Polman	
07.50	What we have learned from Phase II and III studies in RRMS Ludwig Kappos (Basel, Switzerland)	
08.05	Sphingosine-1-phosphate (S1P) receptor modulation: effects on the immune and central nervous system Jerold Chun (San Diego, California, USA)	
08.25	Oral fingolimod: Phase III in PPMS Alan Thompson (London, United Kingdom)	
08.35	Questions and answers/Closing remarks	
09.00-10.00	Plenary Session 2	Room 517
	<p>Co-Chairs: Jack Antel (Montréal, Québec, Canada) and Hans-Peter Hartung (Düsseldorf, Germany)</p> <p>ECTRIMS Lecture What Can we Learn from Treating Multiple Sclerosis? Chris Polman (Amsterdam, Netherlands)</p>	
10.00-10.30	Coffee Break and Poster Viewing	Room 220D

SCIENTIFIC PROGRAM

FRIDAY, SEPTEMBER 19, 2008 (CONT.)

10.30-12.00		Parallel Session 5	Room 517A
		Advances in Imaging Techniques Co-Chairs: Douglas Arnold (Montréal, Québec, Canada) and Massimo Filippi (Milan, Italy)	
10.30	43*	OCT: window on multiple sclerosis Laura Balcer (Philadelphia, Pennsylvania, USA)	
10.50	44*	New insights into multiple sclerosis pathogenesis based on post-mortem magnetic resonance imaging studies Frederik Barkhof (Amsterdam, Netherlands)	
11.10	45	Whole brain magnetization transfer histogram metrics predict clinical disability in multiple sclerosis patients: a 5-year follow-up study Nancy Richert (Bethesda, Maryland, USA)	
11.25	46	Evaluation of multiple sclerosis lesions using gradient echo plural contrast imaging Pascal Sati (St. Louis, Missouri, USA)	
11.40	47	Relation between leakage of the blood-brain barrier as assessed by Gadofluorine M-enhanced magnetic resonance imaging and infiltration of macrophages in experimental autoimmune encephalomyelitis Guido Stoll (Wuertzburg, Germany)	
10.30-12.00		Parallel Session 6	Room 517D
		Predicting Outcomes in MS Co-Chairs: Michel Clanet (Toulouse, France) and Aaron Miller (New York, New York, USA)	
10.30	48*	Clinical and demographic predictors of early multiple sclerosis course Emmanuelle Waubant (San Francisco, California, USA)	
10.50	49*	Genes and outcomes in multiple sclerosis: predicting disease severity George Ebers (Oxford, United Kingdom)	
11.10	50*	Imaging metrics that predict outcomes Maria Pia Sormani (Genoa, Italy)	
11.30	51	Baseline magnetic resonance imaging predictors for conversion to clinically definite multiple sclerosis and McDonald multiple sclerosis, based on integrated 3-year data from the BENEFIT study Bastiaan Moraal (Amsterdam, Netherlands)	
11.45	52	The Multiple Sclerosis Severity Score (MSSS) re-examined: Expanded Disability Status Scale rank stability in the MSBase dataset increases 5 years after onset of multiple sclerosis Helmut Butzkueven (Melbourne, Australia)	
12.00-13.00		ACTRIMS Steering Committee Meeting	Room 514A
12.00-14.00		Lunch and Poster Viewing	Room 220D
12.45 - 13.45		Sponsored Satellite Symposium – Bayer HealthCare and Genzyme	Room 517A
		Researching the Potential for a New Treatment Paradigm: Alemtuzumab in MS Chair: Paul O'Connor (Toronto, Ontario, Canada)	
12.45		Welcome Paul O'Connor	
12.50		Mechanism of action Joanne Jones (Cambridge, United Kingdom)	
13.10		Current clinical evidence Krzysztof Selmaj (Lodz, Poland)	
13.25		Phase III trial programme Edward Fox (Round Rock, Texas, USA)	
13.40		Discussion	

* Invited lectures

SCIENTIFIC PROGRAM

FRIDAY, SEPTEMBER 19, 2008 (CONT.)

14.00-15.40		Parallel Session 7	Room 517A
		Emerging Therapies Co-Chairs: Giancarlo Comi (Milan, Italy) and Rhonda Voskuhl (Los Angeles, California, USA)	
14.00	53*	Overview of oral and IV therapies for multiple sclerosis Ludwig Kappos (Basel, Switzerland)	
14.20	54*	Treatments that target macrophages and microglia Samia Khoury (Boston, Massachusetts, USA)	
14.40	55	Alemtuzumab significantly increases the proportion of clinically disease-free patients with relapsing-remitting multiple sclerosis compared to subcutaneous interferon beta-1a: results from a phase 2 study Krzysztof Selmaj (Lodz, Poland)	
14.55	56	TERMS (Tovaxin® for Early Relapsing MS) phase 2b placebo-controlled trial of autologous T-cell vaccination in patients with clinically isolated syndrome or relapsing remitting multiple sclerosis Edward Fox (Round Rock, Texas, USA)	
15.10	57	Safety, phase I/II study with intrathecal and intravenous injection of mesenchymal stem cells in patients with multiple sclerosis and amyotrophic lateral sclerosis Dimitrios Karussis (Jerusalem, Israel)	
15.25	84	Late Breaking News: Treatment of PML unfolding during monotherapy with natalizumab Ralf Gold (Bochum, Germany)	
14.00-15.30		Parallel Session 8	Room 517D
		Clinical Trial Design Issues Co-Chairs: Gilles Edan (Rennes, France), Henry McFarland (Bethesda, Maryland, USA)	
14.00	58*	Clinical trial design: the present and future Jerry Wolinsky (Houston, Texas, USA)	
14.20	59*	Head-to-head studies in multiple sclerosis: what do they tell us? Hans-Peter Hartung (Düsseldorf, Germany)	
14.40	60*	The ethics of clinical trials in developing countries Edgardo Cristiano (Buenos Aires, Argentina)	
15.00	61	Sample sizes for brain atrophy outcome measures in clinical trials for secondary progressive multiple sclerosis Frederik Barkof (Amsterdam, Netherlands)	
15.15	62	The search for responsive clinical endpoints in primary progressive multiple sclerosis Libertje VAE Bosma (Amsterdam, Netherlands)	
15.30-17.00		Poster Session 2 and Coffee Break	Room 220D
		Posters P451 – P498, with authors present	
17.00-17.45		Hot Topic 4	Room 517A
		Bone Marrow Transplantation: Pros and Cons Co-Chairs: Mark Freedman (Ottawa, Ontario, Canada) and Neil Scolding (Bristol, United Kingdom)	
17.00	63*	Evidence of effectiveness balances risk in bone marrow transplantation Athanasios Fassas (Thessaloniki, Greece)	
17.15	64*	Continuing brain damage post stem cell transplantation Imke Metz (Göttingen, Germany)	
17.30	65	Dose matters: different immunological effects following a reduced- or high-intensity autologous hematopoietic stem cell transplantation regimen in patients with multiple sclerosis Paolo Muraro (London, United Kingdom)	

SCIENTIFIC PROGRAM

FRIDAY, SEPTEMBER 19, 2008 (CONT.)

17.00-17.45		Hot Topic 5	Room 517D
		Management of Treatment Failure Co-Chairs: Kenneth Johnson (Baltimore, Maryland, USA) and Per Soelberg-Sorenson (Copenhagen, Denmark)	
17.00	66*	Defining treatment failure Jordi Río (Barcelona, Spain)	
17.15	67*	Management of treatment failure Richard Rudick (Cleveland, Ohio, USA)	
17.30	68	A post-marketing evaluation of the impact of neutralizing antibodies on the effectiveness of interferon beta in relapsing remitting multiple sclerosis Damiano Paolicelli (Bari, Italy)	
17.00-17.45		Hot Topic 6	Room 520
		Novel Cytokine, Chemokine and Adhesion Molecules Co-Chairs: Alberto Allain Gabbai (Sao Paulo, Brazil) and Abdolmohamad Rostami (Philadelphia, Pennsylvania, USA)	
17.00	69*	Novel adhesion molecules of the blood-brain barrier Alexander Prat (Montréal, Québec, Canada)	
17.15	70*	Multiple sclerosis immunologic and clinical behavior in parasitic infections Jorge Correale (Buenos Aires, Argentina)	
17.30	71	Notch1 signaling regulates remyelination in the adult central nervous system Gareth John (New York, New York, USA)	
18.00 - 19.00		Sponsored Satellite Symposium – Biogen Idec and Elan	Room 517D
		Discovering New Pathways in MS Chair: Bruce Trapp (Cleveland, Ohio, USA)	
		Understanding the pathophysiology of MS Bruce Trapp (Cleveland, Ohio, USA)	
		Defining the pathway of a new oral therapy Amit Bar-Or (Montréal, Québec, Canada)	
		Transforming discovery into care Richard Rudick (Cleveland, Ohio, USA)	
		The future promise of MS research Ralf Gold (Bochum, Germany)	
19.15 – 20.15		Sponsored Satellite Symposium – EMD Serono	Room 517A
		Oral Therapy: Increasing Treatment Options in MS Co-Chairs: Pierre Duquette (Montréal, Québec, Canada) and Maghild Sandberg-Wollheim (Lund, Sweden)	
19.15		Welcome	
19.20		Oral MS therapy Peter Rieckmann (Vancouver, British Columbia, Canada)	
19.35		The role of lymphocytes in the pathophysiology of MS Patrick Vermersch (Lille, France)	
19.50		Preferential lymphocyte depletion in MS Thomas Leist (Philadelphia, Pennsylvania, USA)	
20.05-20.15		Questions and panel discussion	
20.30		Congress Gala Dinner at Windsor Station	